Predictors of haemoglobin levels and of changes in these levels, focusing on anaemia and polycythaemia after administration of the sodium-glucose cotransporter-2 inhibitor tofogliflozin

Diabetes Obes Metab. 2022 Dec;24(12):2469-2473. doi: 10.1111/dom.14836. Epub 2022 Sep 12.

Authors

Yasuhiro Matsubayashi¹, Alkihiro Yoshida^{1

2}, Hideki Suganami³, Momoko Oe^{1

2}, Takaaki Sato¹, Yuta Yaguchi¹, Kazuya Fujihara¹, Takaho Yamada¹, Shiro Tanaka⁴, Kohei Kaku⁵, Hirohito Sone¹

Affiliations

¹ Department of Hematology, Endocrinology and Metabolism, Faculty of Medicine, Niigata University, Niigata, Japan.
² Kowa Company, Ltd, Tokyo, Japan.
³ Clinical Data Science Dept., Kowa Co., Ltd, Japan.
⁴ Department of Clinical Biostatistics, Graduate School of Medicine Kyoto University.
⁵ Kawasaki Medical School, Okayama, Japan.

No abstract available

MeSH terms

Anemia* / chemically induced
Benzhydryl Compounds / adverse effects
Diabetes Mellitus, Type 2* / complications
Diabetes Mellitus, Type 2* / drug therapy
Glucose
Hemoglobins
Humans
Polycythemia*
Sodium
Sodium-Glucose Transporter 2 Inhibitors* / adverse effects

Substances

6-((4-ethylphenyl)methyl)-3',4',5',6'-tetrahydro-6'-(hydroxymethyl)spiro(isobenzofuran-1(3H),2'-(2H)pyran)-3',4',5'-triol
Sodium-Glucose Transporter 2 Inhibitors
Benzhydryl Compounds
Hemoglobins
Glucose
Sodium